The introduction of transcatheter aortic valve replacement (TAVR) into clinical practice has revolutionized interventional cardiology, however it is a valuable option for an inoperable patient with aortic stenosis Severe or high-risk population, TAVR is associated with risk of cerebral embolization and ischemic vascular events and possible neurological impairment. The estimate of these complications is variable, but they have been reported early and late after the procedure. Additionally, the reported incidence of bleeding associated with TAVI is relatively high. The incident complication required adequate antithrombotic treatment during and after the procedure, however, despite current guideline recommendations, the optimal antithrombotic is not very well established. Introduction: Severe aortic stenosis (AS) is a major cause of mortality and morbidity in older adults up to bimodal age. distribution, degenerative calcification of the tricuspid valve is the main cause of AS in the population, unlike the etiology in younger patients which is: calcification of the bicuspid valve or rheumatic heart disease. 1 The disease burden is high with a prevalence of 3.4% 2. With the progressive nature of the disease and increased severity of symptoms, surgery has become the gold standard for patients with symptomatic AS. However, up to 30% of cases are considered too high risk for conventional valve replacement surgery and remain untreated and experience a poor prognosis. Fortunately, with the introduction of TAVR, it provides a valuable option for patients who are inoperable or at high risk for surgery. The annual number of candidates eligible for this procedure is expected to be 27,000 in 19 European countries and North America, according to a recent meta-analysis. ..... middle of article......, Welsh R, Feindel C, Lichtenstein S. Transcatheter aortic valve implantation: a position statement from the Canadian Cardiovascular Society. Can J Cardiol. 2012;28:520-8.26-Noble S, Asgar A, Cartier R, Virmani R, Bonan R. Pathological analysis after implantation of the CoreValve ReValving system.EuroIntervention 2009;5:78–85.27-Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation.Am J Cardiol 2011;108:1772–6.28- Aspirin versus aspirin þ Clopidogrel after transcatheter aortic valve implantation: the ARTE trial. 2012. Available at: http://clinicaltrials.gov/ct2/show/nct01559298?term¼nct01559298&rank¼1. Accessed May 30, 2012.29-Jean-Philippe Collet, Gilles Montalescot, Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field? EuroIntervention 2013;9:S43-S47